Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Avenzo Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: https://avenzotx.com/
Year Founded: 2022
Status: Private
BioCentury | Mar 4, 2025
Data Byte
Bispecifics overtake ADCs in China deals
Western biopharmas signed more deals for bispecifics than ADCs with China biotechs last year
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Apr 18, 2024
Product Development
CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
BioCentury | Mar 28, 2024
Finance
Venture report: Liquidity coming for Boundless’ syndicate; plus Avenzo’s $150M round
As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public
BioCentury | Jan 4, 2024
Deals
Pair of Novo deals within Flagship framework among many ahead of JPM
Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | May 25, 2023
Finance
Turning Point team quietly reforms at Avenzo, raises $196M
Led by Athena Countouriotis, cancer start-up hopes to build pipeline by in-licensing ADCs, bispecifics or small molecules
Items per page:
1 - 10 of 10